16 Sep, 2022
With the theme of “Only the innovators can make steady progress”, the press conference of the 2021 Chinese Biopharma Companies Innovation TOP 100 Series Lists was held online on September 16, 2022. Genor Biopharma remained included in the Chinese Antibody Drug Companies Innovation TOP 30.
08 Sep, 2022
Genor Biopharma (Stock code: 6998.HK) announced today that the first patient has been successfully dosed in a Phase I/II clinical trial of GB261(CD20/CD3, bispecific antibody) in China.
31 Aug, 2022
Genor Biopharma (Stock code: 6998.HK) today announced its interim results for 2022, sharing the company's business progress, financial data, and highlights during the period.
Genor Biopharma and Abogen Biosciences Announce a Cooperative Development Agreement to Jointly Develop Globally Innovative mRNA Products and Related Pharmaceuticals
24 Jun, 2022
Genor Biopharma (Stock code: 6998.HK) announced today that the company has entered into a cooperative development agreement (the “Cooperative Development Agreement”) with Suzhou Abogen Biosciences Co., Ltd (“Abogen”) to jointly develop globally innovative mRNA products and related pharmaceuticals.
Genor Biopharma obtains IND approval from NMPA to commence the phase I/II clinical trial of GB263T, the world's first EGFR/cMET/cMET tri-specific antibody
06 Jun, 2022
Genor Biopharma (Stock code: 6998.HK) announced today that the company has obtained the IND approval from the National Medical Products Administration (NMPA) on June 2, 2022 for the phase I/II clinical trials of GB263T, a novel EGFR/cMET/cMET trispecific therapeutic antibody.